Literature DB >> 16080176

The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines.

Geoff Delaney1, Susannah Jacob, Carolyn Featherstone, Michael Barton.   

Abstract

Radiotherapy utilization rates for cancer vary widely internationally. It has previously been suggested that approximately 50% of all cancer patients should receive radiation. However, this estimate was not evidence-based. The aim of this study was to estimate the ideal proportion of new cases of cancer that should receive radiotherapy at least once during the course of their illness based on the best available evidence. An optimal radiotherapy utilization tree was constructed for each cancer based upon indications for radiotherapy taken from evidence-based treatment guidelines. The proportion of patients with clinical attributes that indicated a possible benefit from radiotherapy was obtained by adding epidemiologic data to the radiotherapy utilization tree. The optimal proportion of patients with cancer that should receive radiotherapy was then calculated using TreeAge (TreeAge Software, Williamstown, MA) software. Sensitivity analyses using univariate analysis and Monte Carlo simulations were performed. The proportion of patients with cancer in whom external beam radiotherapy is indicated according to the best available evidence was calculated to be 52%. Monte Carlo analysis indicated that the 95% confidence limits were from 51.7% to 53.1%. The tightness of the confidence interval suggests that the overall estimate is robust. Comparison with actual radiotherapy utilization data suggests a shortfall in actual radiotherapy delivery. This methodology allows comparison of optimal rates with actual rates to identify areas where improvements in the evidence-based use of radiotherapy can be made. It provides valuable data for radiotherapy service planning. Actual rates need to be addressed to ensure better radiotherapy utilization. Copyright 2005 American Cancer Society.

Entities:  

Mesh:

Year:  2005        PMID: 16080176     DOI: 10.1002/cncr.21324

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  383 in total

Review 1.  Emerging Roles of Electrospun Nanofibers in Cancer Research.

Authors:  Shixuan Chen; Sunil Kumar Boda; Surinder K Batra; Xiaoran Li; Jingwei Xie
Journal:  Adv Healthc Mater       Date:  2017-12-06       Impact factor: 9.933

Review 2.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

3.  Patients' characteristics informing practice: improving individualized nursing care in the radiation oncology setting.

Authors:  Pauline M Rose
Journal:  Support Care Cancer       Date:  2018-05-04       Impact factor: 3.603

4.  Radiation therapy quality assurance in clinical trials--Global Harmonisation Group.

Authors:  Christos Melidis; Walter R Bosch; Joanna Izewska; Elena Fidarova; Eduardo Zubizarreta; Satoshi Ishikura; David Followill; James Galvin; Ying Xiao; Martin A Ebert; Tomas Kron; Catharine H Clark; Elizabeth A Miles; Edwin G A Aird; Damien C Weber; Kenneth Ulin; Dirk Verellen; Coen W Hurkmans
Journal:  Radiother Oncol       Date:  2014-05-08       Impact factor: 6.280

5.  Etoposide radiosensitizes p53-defective cholangiocarcinoma cell lines independent of their G2 checkpoint efficacies.

Authors:  Arunee Hematulin; Sutiwan Meethang; Kitsana Utapom; Sopit Wongkham; Daniel Sagan
Journal:  Oncol Lett       Date:  2018-01-09       Impact factor: 2.967

6.  12-Lipoxygenase is a Critical Mediator of Type II Pneumocyte Senescence, Macrophage Polarization and Pulmonary Fibrosis after Irradiation.

Authors:  Eun Joo Chung; Jessica L Reedy; Seokjoo Kwon; Shilpa Patil; Luca Valle; Ayla O White; Deborah E Citrin
Journal:  Radiat Res       Date:  2019-08-02       Impact factor: 2.841

7.  Tumor cells, but not endothelial cells, mediate eradication of primary sarcomas by stereotactic body radiation therapy.

Authors:  Everett J Moding; Katherine D Castle; Bradford A Perez; Patrick Oh; Hooney D Min; Hannah Norris; Yan Ma; Diana M Cardona; Chang-Lung Lee; David G Kirsch
Journal:  Sci Transl Med       Date:  2015-03-11       Impact factor: 17.956

8.  Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.

Authors:  Joseph C Cheng; Aiping Bai; Thomas H Beckham; S Tucker Marrison; Caroline L Yount; Katherine Young; Ping Lu; Anne M Bartlett; Bill X Wu; Barry J Keane; Kent E Armeson; David T Marshall; Thomas E Keane; Michael T Smith; E Ellen Jones; Richard R Drake; Alicja Bielawska; James S Norris; Xiang Liu
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

Review 9.  Redox-modulated phenomena and radiation therapy: the central role of superoxide dismutases.

Authors:  Aaron K Holley; Lu Miao; Daret K St Clair; William H St Clair
Journal:  Antioxid Redox Signal       Date:  2014-02-14       Impact factor: 8.401

Review 10.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.